Product Description
Etanercept is used alone or with other medications to relieve the symptoms of certain autoimmune disorders (conditions in which the immune system attacks healthy parts of the body and causes pain, swelling, and damage). Etanercept is in a class of medications called tumor-necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflammation. Etanercept injection comes as a solution (liquid) in a prefilled syringe and an automatic injection device, and as a powder to be mixed with a provided liquid. Etanercept is injected subcutaneously (under the skin). It is usually injected once a week.
Mechanisms of Action: TNF Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additional Commercial Interests: Pfizer
Clinical Description
Countries in Clinic: Australia, Bulgaria, China, Hungary, Italy, Moldova, Netherlands, Poland, Romania
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Acute Respiratory Distress Syndrome|Arthritis, Juvenile|Arthritis, Rheumatoid
Phase 2: Colorectal Cancer|Liver Cancer|Type 2 Diabetes
Phase 1: Autoimmune Disease Unspecified|Healthy Volunteers|Spondylitis, Ankylosing
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2023TXI01 | P2 |
Not yet recruiting |
Type 2 Diabetes |
2026-01-01 |
50% |
| MB04-C-01-23 | P3 |
Recruiting |
Arthritis, Rheumatoid |
2025-10-01 |
21% |
| MB04-C-01-23 | P3 |
Active, not recruiting |
Arthritis, Rheumatoid |
2025-04-15 |
|
| STARS | P3 |
Recruiting |
Arthritis, Rheumatoid|Arthritis, Juvenile |
2025-02-28 |
23% |
| 2012-001145-40 | P3 |
Completed |
Arthritis, Rheumatoid|Acute Respiratory Distress Syndrome|Arthritis, Juvenile |
2024-11-17 |
|
| MB04-A-01-23 | P1 |
Active, not recruiting |
Autoimmune Disease Unspecified|Healthy Volunteers |
2024-09-17 |
69% |
| 2006-7041-83/hah | P2 |
Not yet recruiting |
Colorectal Cancer|Liver Cancer |
2019-11-10 |
|
| CTR20150555 | P1 |
Active, not recruiting |
Spondylitis, Ankylosing |
None |